Research record

Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.

Human study published by Transplantation and cellular therapy, indexed because it matched monitored longevity research terms. Inclusion in this index does not establish that an intervention is effective or safe.

Plain-language guide

Five questions to ask about this record

What this is
human-study record from Transplantation and cellular therapy.
Why it may matter
It matched a longevity topic and may show how that evidence area is developing.
Evidence
Automated topic match 100%; this is not a medical rating.
Main limitation
One research record does not prove safety, effectiveness, or usefulness for an individual.
What changed
Source metadata was published or refreshed November 11, 2023.
Where to verify
Open the primary source below for methods, population, results, and limitations.
Published
November 11, 2023
Journal
Transplantation and cellular therapy
Authors
Hany Elmariah, Salman Otoukesh, Ambuj Kumar, Haris Ali, Shukaib Arslan, Geoffrey Shouse, Hoda Pourhassan, Taiga Nishihori, Rawan Faramand, Asmita Mishra, Farhad Khimani, Hugo Fernandez, Aleksandr Lazaryan, Michael Nieder, Lia Perez, Hien Liu, Ryotaro Nakamura, Joseph Pidala, Guido Marcucci, Stephen J Forman, Claudio Anasetti, Frederick Locke, Nelli Bejanyan, Monzr M Al Malki
DOI
10.1016/j.jtct.2023.11.010
Evidence class
human-study
Record status
published
Match confidence
100%
Source feed
PubMed
Automated source synopsis

Human study published by Transplantation and cellular therapy, indexed because it matched monitored longevity research terms. Inclusion in this index does not establish that an intervention is effective or safe.

Evidence snapshot

What the source actually supports

Evidence stage
Human study
Study design
Clinical Trial, Phase II; Journal Article
Evidence population
Human evidence
Participants
Not reported
Population
Not reported
Duration
Not reported
Intervention
Comparator
Not reported
Outcomes measured
Reported result
No reusable finding-level result is available in this record.

Main limitationBibliographic metadata identifies the record but does not provide enough reusable detail to summarize its population, comparison, findings, or effect size.

Safety and approvalThis index record does not establish safety, effectiveness, dose, or suitability for any person. A publication record is not a regulatory approval or treatment recommendation.

Source supportBibliographic citation metadata and controlled indexing terms only. Read the linked source for methods and results.

Evidence stage · human-studyThis describes the study type, not whether an intervention is safe or effective.
Lab or animalHuman studyRandomized trialEvidence synthesis
Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 95% · update recency 65%. These figures help sort records; they are not medical ratings.

BibTeX · RIS

rapamycin
Read the original source →Export JSON